ABSTRACT Potent in vitro inhibition of thymidylate synthase (5,lO-methylenetetrahydrofolate:dUMP C-methyltransferase, EC 2.1.1.45) by 5-fluoro-2'-deoxyuridylate requires 5,10-methylenetetrahydrofolate. The cytotoxicity of 5-fluoro-2'-deoxyuridine towards cultured L1210 mouse leukemia cells is reduced when intracellular reduced folates are depleted, either by limiting the source in media or by inhibition of dihydrofolate reductase with methotrexate. Likewise, the intracellular amount of 5-fluoro-2'-deoxyuridylate covalently bound to thymidylate synthase in L1210 cells treated with 5-fluoro-2'-deoxyuridine is greatly diminished when cells are depleted of folate cofactors. The folate requirement for optimal growth of L1210 cells is lower than that required for maximal cytotoxicity of 5-fluoro-2'-deoxyuridine. These findings provide a biochemical rationale that may be useful in designing clinical protocols that use 5-fluorinated uracil analogs. bursts. The suspensions were heated at 1000 for 90 sec and 50-Al (ca 0.4 mg of protein) samples were electrophoresed on slab gels of 12% polyacrylamide containing 0.1% NaDodSO4 (9, 10). The gel tracts were sliced into seventeen 0.5-cm fractions, each of which was incubated in 1 ml of NCS (Amersham/Searle Co.) at 60°overnight and assayed for radioactivity in a liquid scintillation system.
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5-Fluorouracil (FUra) and methotrexate (MTX) have been used both separately and in combination to treat a variety of neoplasms. With few exceptions, clinical protocols for single and multiple drug cancer chemotherapy have of necessity been empirically derived, and often yield inconclusive data as to the efficacy of such agents. Indeed, while the combination of cyclophosphamide, MTX, and FUra has been acclaimed a significant breakthrough in adjuvant treatment of human breast cancer (1) , studies on experimental systems have yielded conflicting reports as to whether MTX and FUra are additive, synergistic (2) (3) (4) (5) , or antagonistic (6, 7) . It is reasonable to believe that a fundamental knowledge of the mechanism of action of such drugs, together with their effects on cellular metabolism and growth, might be used to predict and modify their effects and thus be useful in achieving a more rational approach for design of schedules and combinations. In (11) . In recent years the molecular mechanism of the interaction of FdUMP with thymidylate synthase has been established (12) (13) (14) (15) (16) , and the salient point with regard to this paper is that CH2-H4folate is required for potent inhibition. In the absence of this cofactor, FdUMP binds poorly to the enzyme (K -10 ,uM) (12, 13, 17) , whereas the presence of CH2-H4folate results in a ternary complex in which FdUMP is bound some 7 to 8 orders of magnitude more tightly (13) . This dramatic increase in affinity results in part from two-ligand synergism in formation of reversible complexes (13, 17) , but for the most part is due to the formation of covalent bonds that link the enzyme to FdUMP and CH2-H4folate as shown in Fig. 1 (12) (13) (14) (15) (16) (20) and mammalian (15) sources are dimers with a subunit molecular weight of ca 35,000. The covalent bonds of the FdUMP-CH2-H4folate-enzyme complex are stable toward denaturants (12) (13) (14) (15) (16) and the 35,000-dalton complex can be readily identified by NaDodSO4 gel electrophoresis (15, 16) ; in contrast, in the absence of CH2-H4folate, FdUMP is bound poorly to thymidylate synthase by noncovalent forces (12, 13, 17) , and binary FdUMP-enzyme complexes are unstable towards denaturing conditions. L1210 cells were grown for 13 (13, 17) .
For example, high concentrations of the noncytotoxic analog 10-CH3-folic acid can partially reverse the MTX antagonism of FdUrd on L1210 cells in culture (unpublished data). Bertino et al. (5) have recently applied a similar rationale in designing an MTX-FUra schedule for treatment of the sarcoma 180 mouse tumor model. These workers surmised that although MTX would depleteH4folates, sufficiently high intracellular concentrations of the drug might in addition synergize binding of FdUMP to thymidylate synthase, as it does in vitro (13) , and override the antagonism observed at low MTX concentrations.
Indeed, significant therapeutic enhancement was observed when tumor-bearing animals were treated with high doses of MTX 2 hr prior to FUra administration. While the basis for the success of this schedule remains unproven, a salient point is that its design was based on biochemical reasoning rather than the empiricism frequently used in developing such regimens.
Lastly, it may be quite relevant that, as shown here for L1210 cells, intracellular H4folates can be sufficient for optimal growth but not for optimal inhibition of thymidylate synthase by FdUMP. This relationship may vary in different cells for a number of reasons; for example, cells with higher levels of thymidylate synthase would require higher concentrations of CH2-H4folate to achieve optimal inhibition of this enzyme by FdUMP. Indeed, thymidylate synthase increase has been identified as a progression-linked alteration that parallels the degree of malignancy or growth rate in a variety of rat hepatomas (21) . Thus, the possibility exists that intracellular folate cofactors in tumors that are marginally responsive towards 5-FUra or FdUrd may be optimal for their growth, but not for inhibition of thymidylate synthase by FdUMP. Should this be the case, administration of a reduced folate, such as folinic acid, might increase the effectiveness of thymidylate synthase ihhibition by FdUMP while H4folate-independent effects of FUra would remain unchanged; it is possible that such tumors could be made more responsive towards FUra or FdUrd with a resultant increase in the therapeutic index.
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